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MicroRNAs (miRNAs) are small non-coding RNAs approximately 22 nucleotides in length
that function as regulators of gene expression. Dysregulation of miRNAs has been associ-
ated with initiation and progression of oncogenesis in humans. Our group has previously
described a unique miRNA expression signature, including the MIR200 family member
MIR141, which can differentiate papillary thyroid cancer (PTC) cell lines from a control thy-
roid cell line. An investigation into the expression of MIR141 in a series of archival thyroid
malignancies [n=140; classic PTC (cPTC), follicular variant PTC, follicular thyroid carci-
noma, Hashimoto thyroiditis (HT), or control thyrocytes] was performed. Each cohort had a
minimum of 20 validated samples surgically excised within the period 1980–2009. A sub-
set of the HT and cPTC cohorts (n=3) were also analyzed for expression ofTGFβR1, a key
member of theTGFβ pathway and known target of MIR141. Laser capture microdissection
was used to specifically dissect target cells from formalin-fixed paraffin-embedded archival
tissue. Thyrocyte- and lymphocyte-specific markers (TSHR and LSP1, respectively), con-
firmed the integrity of cell populations in the HT cohort. RNA was extracted and quantitative
RT-PCR was performed using comparative CT (∆∆CT) analysis. Statistically significant
(p<0.05) differential expression profiles of MIR141 were found between tissue types.
HT samples displayed significant downregulation of MIR141 compared to both cPTC and
control thyrocytes. Furthermore, TGFβR1 expression was detected in cPTC samples but
not in HT thyrocytes. It is postulated that the downregulation of this miRNA is due, at
least in part, to its involvement in regulating theTGFβ pathway.This pathway is exquisitely
involved in T-cell autoimmunity and has previously been linked with HT. In conclusion, HT
epithelium can be distinguished from cPTC epithelium and control epithelium based on
the relative expression of MIR141.
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INTRODUCTION
Hashimoto thyroiditis (HT) is a chronic autoimmune disor-
der characterized by lymphocytic inflammation of the thyroid.
This infiltration leads to apoptosis of thyrocytes and hypothy-
roidism. HT is the most common form of thyroiditis, with a
strong prevalence for women over the age of 40 (Rosai, 2004).
The triggers for this autoimmune response appear to be both
humoral and cellular, with a complex etiology involving both
genetic and environmental factors (Eschler et al., 2011). HT is
associated with an increased incidence of papillary thyroid car-
cinoma (PTC). However, the relationship between HT and PTC
remains controversial, with some arguing that the increased rate
of screening in HT patients confounds the association between
the two. However, RET/PTC chromosomal translocations, which
were originally haled to be a unique biomarker of PTC, have
been identified in greater than 95% of HT tissue samples, 84%
of which had no evidence of malignancy (Sheils et al., 2000a).
This evidence implies a shared molecular etiology between HT
and PTC.
Carcinomas of the thyroid are the most common endocrine
malignancy (Parkin et al., 2005, 2010). The most common thyroid
carcinoma is the well-differentiated classic PTC (cPTC), which
accounts for an estimated 80% of thyroid cancers. cPTC is typ-
ically easily recognized microscopically due to its characteristic
papillae and optically clear nuclei. The papillae are frequently
associated with the formation of follicles, the ratio of which vary
greatly (Rosai, 2004). However, other subtypes of thyroid carci-
noma can be more difficult to diagnose. The follicular variant of
PTC (fvPTC) composes entirely or almost entirely of follicles. The
diagnosis of fvPTC is primarily based on nuclear alterations associ-
ated with cPTC. Its invasiveness and incidence of nodal metastases
also aid diagnoses. Follicular carcinoma of the thyroid (FTC) is
usually a solitary neoplasm with a microscopic appearance vary-
ing from well-formed follicles to solid growth patterns (Rosai,
2004). Hence, accurate diagnosis of certain thyroid carcinomas,
in particular the differential diagnoses of fvPTC and FTC may be
problematic. Given the difficulties in differentiating between sub-
types, and with a view to understanding the underlying pathology,
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thyroid cancer research is ongoing with a view to identifying more
robust discriminators of disease and prognosis.
Profiling of microRNA (miRNA) dysregulation is a potential
diagnostic tool (Braun and Hüttelmaier, 2011; Marini et al., 2011).
Many miRNAs display exquisite tissue specificity that may aid in
determining the tumor tissue-of-origin. It has been found that
miRNA classification was more accurate than messenger RNA
(mRNA) classification in determining tissue-of-origin in poorly
differentiated tumors (Rosenfeld et al., 2008). An estimated 50%
of miRNAs are located at genomic regions linked to cancer. Nearly
every type of tumor analyzed by miRNA profiling has shown
significantly altered miRNA profiles compared to normal counter-
parts (Calin and Croce, 2006). Investigation into miRNA deregu-
lation in PTC has identified aberrant miRNA expression profiles
in PTCs compared to normal thyroid (He et al., 2005; Cahill
et al., 2006; Pallante et al., 2006, 2010; Visone et al., 2007; Aherne
et al., 2008). Cahill et al. (2006) identified a miRNA signature
profile for a cPTC cell line that displays significant upregulau-
tion of MIR141. In the present study, an investigation into the
expression of MIR141 in a series of archival thyroid malignan-
cies [cPTC, fvPTC, FTC, HT, or control (no evidence of disease
or goiter tissues) tissues] was performed, with an aim to elucidat-
ing the expression MIR141 across subtypes of follicular thyroid
neoplasia. Each cohort had a minimum of 20 validated samples
surgically excised within the period 1980–2009. Multiple mem-
bers of the TGFβ pathway, including transforming growth factor,
beta receptor 1 (TGFβR1), have been identified to be direct tar-
gets of MIR141 (Braun et al., 2010; Senanayake et al., 2012). This
pathway is involved in signaling for the cytokine IL-2, which has a
well documented association with HT (Weijl et al., 1993). Hence
a subset of the cPTC and HT cohort were analyzed for TGFβR1
gene expression.
MATERIALS AND METHODS
ETHICAL APPROVAL
Full ethical approval was obtained for this study from the Joint St.
James’s Hospital/Adelaide and Meath National Children’s Hospital
Research Ethics Committee.
TISSUE SAMPLE
All samples chosen for this analysis were from different thyroid
tissues excised between 1980 and 2009. All samples were derived
from an Irish population to limit geographical variation. A cohort
of 140 archival cases of formalin-fixed paraffin-embedded (FFPE)
tissues was obtained from the archives at St. James’s Hospital. The
cohort comprised of 30 control (no evidence of malignancy or
goiter) thyroid tissues, 30 cPTC tissues, 28 fvPTC tissues, 26 FTC
tissues, and 26 HT tissues. All tissues had been assessed by a regis-
tered histopathologist and diagnoses confirmed according to the
World Health Organisation classification guidelines.
LASER CAPTURE MICRODISSECTION
The FFPE tissue were cut using a HM325 rotary microtome (MSC,
Dublin, Ireland) to 7µm, mounted on uncharged slides and dried
on a heating block to remove excess moisture. Slides were dewaxed
and hematoxylin and eosin stained using the automated Tissue-
Tek DRS 2000 Autostainer (Sakura, CA, USA). Stained slides
were mounted onto an Arcturusxt Microdissection instrument
(MDS Analytical Technologies, CA, USA). LCM was used to cap-
ture (infrared 810 nm) specific cell populations of interest onto
CapSure® Macro LCM caps (MDS Analytical Technologies, CA,
USA). To confirm the purity of thyrocytes captured from HT
tissues, an area containing lymphocytic infiltrate from the same
7µm section of a representative subset of the HT tissues were also
microdissected on to separate caps for real-time PCR comparison
of thyrocyte-specific and lymphocyte-specific markers. Follow-
ing microdissection the transfer film containing the captured cells
was peeled off the CapSure® macro LCM cap and placed into ster-
ile DNA LoBind tubes (Eppendorf AG, Hamburg, Germany) to
maximize downstream recovery.
NUCLEIC ACID EXTRACTION
RNA was extracted using the RecoverAll™ total nucleic acid
isolation kit optimized for FFPE samples (Applied Biosystems,
CA, USA) following the supplied recommended protocol, with
step B (deparaffinization) omitted as the sections had been
deparaffinized during the H&E staining protocol. The RNA quan-
tity and quality were assessed using the NanoDrop® ND-1000
Spectrophotometer (Wilmington, USA).
miRNA ANALYSIS
Inventoried TaqMan® miRNA Assay (Applied Biosystems, CA,
USA) were used to synthesize single stranded MIR141 and RNU6B
(endogenous control) cDNA according to the supplied TaqMan®
miRNA assays protocol. Reverse transcription was performed on
a Gene Amp PCR System 9600 (Perkin Elmer, MA, USA) with
thermal cycling parameters set as per the TaqMan® miRNA assays
protocol.
Real-time PCR was performed according to TaqMan® miRNA
assays protocol using MIR141-specific or RNU6B-specific inven-
toried real-time miRNA expression assays. The recommended
protocol was adjusted such that the RT product was diluted 1/5 for
use in the assay, with the nuclease-free water adjusted accordingly.
Real-time PCR was performed on an ABI Prism 7900HT Sequence
Detection System (Applied Biosystems, CA, USA) according to
supplied recommended protocol.
mRNA ANALYSIS
Reverse transcription was performed using the High Capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems, CA,
USA) as per manufacturers protocol. Real-time PCR was per-
formed using inventoried TaqMan® Gene Expression Assays
according to manufacturer supplied protocol for thyroid stimu-
lating hormone receptor (TSHR), lymphocyte-specific protein 1
(LSP1), TGFβR1, and the endogenous control glyceraldehydes-3
phosphate dehydrogenase (GAPDH).
DATA ANALYSIS
MicroRNAs and gene expression was measured by relative quan-
titation (RQ). The comparative CT (∆∆CT) method was used
to calculate RQ of mRNA and miRNA expression, using GAPDH
and RNU6B as the endogenous control for mRNA and miRNA
expression, respectively. The same calibrator and threshold levels
were used for all samples. Comparative studies were preformed
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on the data using the SDS2.1 software (Applied Biosystems, CA,
USA). The study was then exported to the Microsoft® Office Excel®
2007 software (Microsoft Corporation, WA, USA), Minitab 16®
(Minitab Inc., USA) and to STATA 8 software (StataCorp LP, TX,
USA) for further analysis. Differentially expressed miRNA patterns
across tissue types were identified by means of a one-way ANOVA.
Statistical significance was set at p< 0.05. The relative expression
(RQ) of TSHR and LSP1 in LCM captured isolated thyrocytes was
compared to that of parallel LCM captured populations contain-
ing lymphocytic infiltration. Statistical significance was set at (±)
twofold expression of thyrocyte-specific populations compared to
parallel populations containing lymphocytic infiltrate.
RESULTS
LASER CAPTURE MICRODISSECTION
Of the 140 thyroid tissues in the cohort, laser capture microdis-
section of 24 tissues did not capture either sufficient quantity or
sufficient quality of cells to extract detectable levels of RNA. Of
the remaining 116 tissues, 111 (95.69%) expressed the endogenous
control, RNU6B, which was selected as the internal normalization
control for miRNA quantitation. Of the 111 samples expressing
the endogenous control, 104 samples also expressed MIR141. This
cohort of samples expressing both RNU6B and MIR141 consisted
of 20 cPTC samples, 20 fvPTC samples, 19 FTC samples, 21 HT
samples, and 24 control samples.
CHARACTERIZATION OF mRNA FROM HT SAMPLES
To confirm the purity of the LCM harvested cell populations (thy-
rocyte and lymphocyte), HT tissues were assayed for thyrocyte-
and lymphocyte-specific markers (TSHR and LSP1, respectively).
mRNA extracted from thyrocytes harvested from HT tissues was
compared to mRNA extracted from interspersed/adjacent areas
of lymphocytic infiltrate captured separately but from the same
7µm sections. As expected, THSR was significantly upregulated
in each isolated thyrocyte population compared to each parallel
sample containing lymphocytic infiltrate. Conversely, LSP1 was
detected in all of the harvested lymphocyte samples but was only
detected in a single thyrocyte sample, albeit displaying signifi-
cant downregulation compared to its paired lymphocyte extract
(Figure 1).
EXPRESSION OFMIR141 IN THYROID TISSUES
A comparison of relative gene expression across the thyroid
cohorts identifies an association between MIR141 expression
and malignant thyroid phenotypes. Analysis of variance (one-
way ANOVA) was performed on log transformed data between
cohorts and identified statistical significance between popu-
lations (p= 0.01, F = 5.40). Residual analysis on log trans-
formed data confirmed normally distributed populations for
each cohort (p< 0.005). Expression of MIR141 was signifi-
cantly downregulated (p< 0.05) in HT samples compared to
both control and cPTC samples (Figure 2). Analysis of vari-
ance also demonstrates that the follicular variant of PTC dis-
plays a statistically significant (p< 0.05) pattern of downregu-
lation of MIR141 expression compared to both control and cPTC
samples.
TGFBR1 IS EXPRESSED IN cPTC BUT NOT IN HT THYROCYTES
A subset of HT and cPTC samples (n= 3/cohort) were assayed
for the expression of TGFβR1, a member of the TGFβ pathway
and known target of MIR141 (Braun et al., 2010). Expression of
TGFβR1 was detected in the all of cPTC samples but not in HT
thyrocytes. Paired HT lymphocytes (n= 3) were also assayed for
TGFβR1 and expression was detectable in these samples. As such,
the cPTC subset (n= 3) were assayed for LSP1 gene expression to
confirm that the TGFβR1 expression detected was not due to lym-
phocyte contamination. LSP1 gene expression was not detectable
in the cPTC samples.
DISCUSSION
Inflammation and thyroid cancer are strongly linked. PTCs have
a penchant to attract a florid of lymphocytic infiltrate. However,
they can persist and metastasize in the presence of this infiltrate.
Normal inflammation is self-limiting because the production of
anti-inflammatory and pro-inflammatory cytokines is tightly reg-
ulated. During normal inflammation, blocking apoptosis provides
time for DNA repair and the production of reactive oxygen species
(ROS) fights against viral threat. However, the failure of mecha-
nisms required for resolving the inflammatory response or the
persistence of the initiating factors can result in chronic inflam-
mation. ROS are mutagens. The blocking of apoptosis in cells that
are gaining oncogenic mutations can lead to tumor progression.
Thus chronic inflammation can act as both an initiator (DNA
damage and growth signals) and as a promoter (blocking apopto-
sis and stimulating cell proliferation), which over time can induce
oncogenesis.
Formalin-fixed paraffin-embedded tissue samples were used in
this study. While FFPE preserves tissue for morphological analysis,
the effect of formalin fixation on nucleic acids can hamper molec-
ular analysis as nucleic acids become cross-linked during fixation.
There are no standardized guidelines for processing FFPE tissues
(Blow, 2007), and as such there can be great variation in the time
between ligation of circulation and fixation. Nucleic acids suffer
damage through fixation. The greater the time prior to fixation, the
greater the exposure to nucleases and modifying enzymes, which
are upregulated during ischemia. Nucleic acids are often irre-
versibly damaged and can become increasingly fragmented during
prolonged storage (Burgemeister, 2011). Mature miRNAs, how-
ever, are approximately 22 nucleotides in length. Due to this small
size they tend not to suffer from the fragmentation effect. Thus,
FFPE tissues tend to yield miRNA more effectively than mRNA.
It has previously been demonstrated that FFPE thyroid tissues are
a suitable resource for miRNA expression analysis (Tetzlaff et al.,
2007; Chen et al., 2008; Sheu et al., 2010). The method used for
miRNA extraction in this study has previously been demonstrated
to yield miRNA with expression levels that positively correlate with
expression levels from snap frozen tissue (Li et al., 2007).
MicroRNAs have emerged as key regulators of the immune
system, displaying unique expression profiles in cells of the adap-
tive and innate immune system (O’Connell et al., 2010). Aberrant
expression of miRNAs has been documented in a range of dis-
eases associated with the immune system, including cancer and
autoimmunity (Calin et al., 2002; Xiao et al., 2008). MiRNA sig-
natures that can distinguish thyroid malignancies in fine needle
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FIGURE 1 | Characterization of isolated thyrocytes from
representative HT tissues.The thyrocyte population was captured
using LCM. An adjacent/interspersed area from the same 7µm section
containing lymphocytic infiltrate was captured on a separate cap for
comparison of gene expression. Relative gene expression ofTSHR
(A) and LSP1 (B) was measured between groups. The isolated
thyrocytes had significantly upregulated levels ofTSHR compared to
populations containing lymphocytic infiltrate. LSP1 was only detected
in 1 sample (HT-1) of isolated thyrocytes and was significantly
downregulated compared to the parallel lymphocyte sample.
*Indicates statistical significance of ± twofold difference in relative
gene expression of thyrocyte-specific populations compared to parallel
populations containing lymphocytic infiltrate.Y -axis is fold change in
gene expression (RQ).
FIGURE 2 | Boxplot of relative quantitation (RQ) of change in
expression of MIR141 across cohorts of follicular thyroid malignancy.
The expression of MIR141 is statistically significantly downregulated in HT
tissues compared to both control and cPTC tissues. The fvPTC tissues also
display a statistically significant downregulation of MIR141 in comparison to
both control and cPTC tissues.Y -axis is log(RQ). *Indicates statistical
significance (p<0.05) as identified by ANOVA, ♦ indicates outliers.
aspiration, FFPE, and fresh surgical samples have been identified
(He et al., 2005; Pallante et al., 2006; Tetzlaff et al., 2007; Chen
et al., 2008; Nikiforova et al., 2008; Sheu et al., 2010; Shen et al.,
2012; Vriens et al., 2012). It has been demonstrated that MIR141
is upregulated in a cell line model of ret/PTC-1 associated PTC
(Cahill et al., 2006). In the current study, we investigated if the pat-
tern of MIR141 expression would translate to clinical specimens.
In fact, the pattern of upregulated MIR141was not observed in the
study sample. This may be due to (a) variation between in vitro
and in vivo expression or (b) the low rate of ret/PTC variants in
the samples analyzed (Table 1).
In this study a significantly decreased expression of MIR141
was identified in thyrocytes isolated from HT tissues compared to
both control and cPTC samples. This is of particular interest as it
has been postulated that HT represents a circumstance in which
thyrocytes are in a state between normal and neoplastic (Sheils
et al., 2000b). Histologically, HT can present with the occurrence
of nuclear clearing and overlapping cells associated with PTC, but
without evidence of malignancy (Rosai, 2004). On a molecular
level, previous studies (Wirtschafter et al., 1997; Sheils et al., 2000a;
Rhoden et al., 2006) detected that up to 95% of HT samples dis-
played evidence of ret/PTC-1 activation, including HT samples
that had no evidence of malignancy. The ret/PTC chromosomal
rearrangement was previously considered to be a hallmark of PTC.
However, evidence of their presence in HT samples indicates a
more complex role of this genetic alteration. Furthermore; the
occurrence of non-specific lymphocytic infiltrate in PTC tissues
has been positively associated with the presence of RET/PTC-1
expression (Sheils et al., 2000b). This has lead to the postulation
that antigenic alterations induced by genetic alterations such as the
activation of c-ret are responsible for eliciting an immune response
within the thyroid tissue. In HT, it is feasible that the presence
of genetic alterations such as c-ret elicit an immune response
to curtail the development of PTC. A subset of patients may be
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Table 1 | Mutational status of RET/PTC-1 and RET/PTC -3 for PTC samples expressing MIR141.
PTC variant Year of biopsy RET/PTC mutation PTC variant Year of biopsy RET/PTC mutation
Classic 1980 Unknown Follicular variant 1986 Negative
Classic 1985 Unknown Follicular variant 1987 Unknown
Classic 1987 Unknown Follicular variant 1989 Negative
Classic 1994 RET/PTC-1 Follicular variant 1991 Negative
Classic 1998 Negative Follicular variant 1991 Negative
Classic 1998 RET/PTC-1 Follicular variant 1992 RET/PTC-1
Classic 2002 Negative Follicular variant 1992 Unknown
Classic 2002 Negative Follicular variant 1992 Unknown
Classic 2002 Negative Follicular variant 1992 Negative
Classic 2003 Negative Follicular variant 1993 RET/PTC-3
Classic 2004 Negative Follicular variant 1996 Unknown
Classic 2004 Negative Follicular variant 2001 Negative
Classic 2004 Negative Follicular variant 2003 Negative
Classic 2004 Negative Follicular variant 2003 Negative
Classic 2004 Negative Follicular variant 2004 Negative
Classic 2004 Negative Follicular variant 2004 Negative
Classic 2005 Negative Follicular variant 2004 Negative
Classic 2005 Negative Follicular variant 2004 Negative
Classic 2005 Negative Follicular variant 2005 Negative
Classic 2005 Negative Follicular variant 2005 Negative
successfully in this regard but with background damage of autoim-
mune destruction of thyroid tissue. However, the relationship
between HT and PTC remains a highly controversial issue.
MIR141 has been confirmed to directly target a number of
genes. Multiple members of the TGFβ pathway have been identi-
fied to be direct targets of MIR141 (Braun et al., 2010; Senanayake
et al., 2012). Braun et al. (2010) demonstrated direct targeting of
TGFβR1 and SMAD family member 2 (SMAD 2). Both TGFβR1
and SMAD2 are negatively regulated by MIR141. These key mem-
bers of the TGFβ signaling pathway act to signal for interleukin-2
(IL-2), a cytokine involved in T-cell proliferation. T-cells play a
crucial role in the development of HT as they secrete inflamma-
tory cytokines in reaction to auto-antigens; primarily TSHR and
thyroid peroxidase (TPO). IL-2 is essential for T-cell determina-
tion of self from non-self. IL-2Rβ/IL-2 knock-out mice developed
a marked increase in T-cell mediated autoimmunity and deregu-
lated T-cell proliferation. Furthermore, IL-2 is used as treatment
for certain cancers, which is documented to result in an increased
risk of HT (Weijl et al., 1993). Thus, the association of MIR141
with the regulation of this pathway may be reflected in its down-
regulation in HT epithelium. The relative expression of TGFβR1
was assayed in a subset of samples (n= 3) in this study. TGFβR1
was found to be expressed in cPTC samples but not in isolated
HT thyrocytes. MIR141 expression is upregulated in these cPTC
samples compared to the isolated HT thyrocyte samples. This ini-
tial data supports the argument for further investigation into the
association of MIR141, the TGFβ signaling pathway and HT.
Thyroid carcinomas frequently present with multiple pheno-
typic tumor-foci within a single thyroid gland. Direct experimen-
tal analysis of these tissues will therefore reflect the predominant
cell type within the tissue which may not be the cell of interest
nor be biologically relevant to the neoplasm under investigation.
MiRNA profiles have been found to distinguish tumor types within
a single thyroid biopsy (Aherne et al., 2008). This highlights the
requirement to extract a pure population of the specific tumor cells
in order to identify and accurately define the molecular processes
in pathogenic lesions. LCM provides a non-damaging microdis-
section process which allows isolation of pure populations while
preserving the integrity of the captured material (Liu, 2010). In
this study, LCM was utilized to specifically select the cell-types
of interest and therefore reduce the confounding factors associ-
ated with whole section analysis. This enforces the accuracy of the
associations identified between MIR141 and malignant thyroid
phenotypes.
In conclusion, HT epithelium can be distinguished from neo-
plastic follicular thyroid epithelium isolated from cPTC and con-
trol epithelium based on the relative expression of MIR141. It is
postulated that the downregulation of this miRNA may be due,
at least in part, to its involvement in regulating the TGFβ signal-
ing pathway. The MIR200 family, including MIR141, have been
demonstrated to directly regulate members of this pathway as part
of a regulatory feedback loop. The preliminary data presented here
in combination with data from the literature (Braun et al., 2010;
Senanayake et al., 2012) leads this postulation to warrant further
investigation. The TGFβ pathway is exquisitely involved in T-cell
autoimmunity and has been linked with HT for some time, as
treatment of cancer patients with IL-2, a downstream target of the
pathway, resulted in increased incidence of HT (Weijl et al., 1993).
Further investigation of MIR141 and its regulatory networks may
aid in elucidating the molecular mechanisms that result in the
fundamental physiological differences between these malignant
thyroid phenotypes.
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